The stock of biOasis Technologies Inc (CVE:BTI) is a huge mover today! About 12,900 shares traded hands. biOasis Technologies Inc (CVE:BTI) has risen 6.00% since October 23, 2016 and is uptrending. It has outperformed by 1.44% the S&P500.
The move comes after 6 months negative chart setup for the $53.24M company. It was reported on Nov, 22 by Barchart.com. We have $1.14 PT which if reached, will make CVE:BTI worth $3.73 million less.
More important recent biOasis Technologies Inc (CVE:BTI) news were published by: Business.Financialpost.com which released: “Podcast: biOasis Technologies Inc CEO Rob Hutchison on how his company is …” on March 29, 2016, also Reuters.com published article titled: “BRIEF-biOasis enters into a license agreement with Vaccinex Inc.”, Marketwired.com published: “biOasis Enters Into a License Agreement With Vaccinex Inc.” on September 21, 2016. More interesting news about biOasis Technologies Inc (CVE:BTI) was released by: Marketwired.com and their article: “biOasis Announces Grant of Stock Options” with publication date: January 31, 2015.
biOasis Technologies Inc. is a development-stage biopharmaceutical company, which is focused on research, development and commercialization of technologies and products that are intended for the treatment of central nervous system diseases and diseases of the brain. The company has a market cap of $53.24 million. The Firm researches and develops products for diagnosis and treatment of neurological diseases and disorders. It currently has negative earnings. It is engaged in the development of its vectors Transcend and Transcendpep for the transport of therapeutic agents across the blood brain barrier (BBB).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.